NYSE:BIO Bio-Rad Laboratories (BIO) Stock Price, News & Analysis $380.58 +8.15 (+2.19%) Closing price 03:59 PM EasternExtended Trading$379.93 -0.65 (-0.17%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Bio-Rad Laboratories Stock (NYSE:BIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bio-Rad Laboratories alerts:Sign Up Key Stats Today's Range$369.33▼$381.8750-Day Range$352.24▼$391.2952-Week Range$236.73▼$396.23Volume167,156 shsAverage Volume307,916 shsMarket Capitalization$10.18 billionP/E Ratio46.13Dividend YieldN/APrice Target$343.33Consensus RatingHold Company Overview Bio-Rad Laboratories, Inc. develops, manufactures and markets products and systems used in life science research and clinical diagnostics. Its life science portfolio includes laboratory instruments, reagents, software and consumables used in areas such as genomics, proteomics, cell biology, biopharmaceutical development and quality control. The company’s clinical diagnostics business provides systems, reagents and software for blood typing, infectious disease testing, diabetes monitoring, quality control and other diagnostic applications. Bio-Rad serves universities, research institutions, biotechnology and pharmaceutical companies, hospitals, clinical laboratories and industrial customers. Founded in 1952 by David and Alice Schwartz, Bio-Rad is headquartered in Hercules, California, and operates through a global network serving customers in North America, Europe, Asia and other international markets. Norman D. Schwartz serves as the company’s chairman, president and chief executive officer.AI Generated. May Contain Errors. Read More Bio-Rad Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreBIO MarketRank™: 1.524067621625 of 5 starsBio-Rad Laboratories scored higher than 30% of companies evaluated by MarketBeat, and ranked 823rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingBio-Rad Laboratories has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and no sell ratings.Downside RiskBio-Rad Laboratories has a consensus price target of $343.33, representing about 9.8% downside from its current price of $380.58.Amount of Analyst CoverageBio-Rad Laboratories has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bio-Rad Laboratories' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-4.20% Earnings GrowthEarnings for Bio-Rad Laboratories are expected to decrease by -4.20% in the coming year, from $9.28 to $8.89 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bio-Rad Laboratories is 46.13, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.08.Price to Earnings Ratio vs. SectorThe P/E ratio of Bio-Rad Laboratories is 46.13, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.59.Price to Book Value per Share RatioBio-Rad Laboratories has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Bio-Rad Laboratories' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.89% of the float of Bio-Rad Laboratories has been sold short.Short Interest Ratio / Days to CoverBio-Rad Laboratories has a short interest ratio ("days to cover") of 4.84.Change versus previous monthShort interest in Bio-Rad Laboratories has recently decreased by 7.20%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBio-Rad Laboratories does not currently pay a dividend.Dividend GrowthBio-Rad Laboratories does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.63 News SentimentBio-Rad Laboratories has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Bio-Rad Laboratories this week, compared to 2 articles on an average week.Search Interest2 people have searched for BIO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bio-Rad Laboratories insiders have not sold or bought any company stock.Percentage Held by Insiders30.34% of the stock of Bio-Rad Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.24% of the stock of Bio-Rad Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bio-Rad Laboratories' insider trading history. Receive BIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIO Stock News HeadlinesBIO (BIO) vs. TMO and DHR: Can Activist Pressure Close Bio-Rad’s Valuation Discount?October 27 at 11:51 AM | insidermonkey.comComparing Bio-Rad Laboratories (NYSE:BIO) & Medpace (NASDAQ:MEDP)October 24 at 3:59 AM | americanbankingnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 27 at 1:00 AM | Weiss Ratings (Ad)Why Bio Rad Laboratories (BIO) Is Back In The SpotlightSeptember 30, 2026 | finance.yahoo.comBio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum TranscriptSeptember 24, 2026 | seekingalpha.comBio-Rad: Favorable Read-Across From Investor EventSeptember 10, 2026 | seekingalpha.comBio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeptember 9, 2026 | seekingalpha.comINSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development InitiativesSeptember 4, 2026 | globenewswire.comSee More Headlines BIO Stock Analysis - Frequently Asked Questions How have BIO shares performed this year? Bio-Rad Laboratories' stock was trading at $303.62 at the beginning of 2026. Since then, BIO shares have increased by 25.3% and is now trading at $380.5830. How were Bio-Rad Laboratories' earnings last quarter? Bio-Rad Laboratories, Inc. (NYSE:BIO) posted its quarterly earnings data on Tuesday, August, 4th. The medical research company reported $2.62 earnings per share for the quarter, beating analysts' consensus estimates of $1.75 by $0.87. The business's revenue for the quarter was down .1% on a year-over-year basis. Read the conference call transcript. Does Bio-Rad Laboratories have any subsidiaries? Bio-Rad Laboratories subsidiaries include Dropworks Inc., Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, Propel Labs - Cell Sorting System Division, QuantaLife, and more. Who are Bio-Rad Laboratories' major shareholders? Top institutional shareholders of Bio-Rad Laboratories include Assenagon Asset Management S.A. (0.55%), Hosking Partners LLP (0.36%), Sivik Global Healthcare LLC (0.03%) and Yousif Capital Management LLC (0.01%). Insiders that own company stock include Andrew J Last, Michael Crowley, Dara Wright and James Barry. View institutional ownership trends. How do I buy shares of Bio-Rad Laboratories? Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bio-Rad Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Rad Laboratories investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alphabet (GOOG), Tesla (TSLA), Alibaba Group (BABA), Micron Technology (MU) and Netflix (NFLX). Company Calendar Last Earnings8/04/2026Today10/27/2026Next Earnings (Confirmed)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BIO's financial health is in the Green zone, according to TradeSmith. BIO has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:BIO CIK12208 Webwww.bio-rad.com Phone(510) 724-7000Fax510-741-5817Employees7,450Year Founded1952Price Target and Rating Average Price Target for Bio-Rad Laboratories$343.33 High Price Target$370.00 Low Price Target$330.00 Potential Upside/Downside-9.8%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$8.25 Trailing P/E Ratio46.13 Forward P/E Ratio41.01 P/E GrowthN/ANet Income$759.90 million Net Margins8.59% Pretax Margin13.53% Return on Equity3.54% Return on Assets2.48% Debt Debt-to-Equity Ratio0.11 Current Ratio3.14 Quick Ratio2.33 Sales & Book Value Annual Sales$2.58 billion Price / Sales3.94 Cash Flow$10.31 per share Price / Cash Flow36.91 Book Value$276.16 per share Price / Book1.38Miscellaneous Outstanding Shares26,740,000Free Float18,626,000Market Cap$10.18 billion OptionableOptionable Beta1.07 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSE:BIO) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Rad Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Rad Laboratories With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
